ADDvise strengthens the management team, recruits COO

19-08-2021   Regulatory press release

Fredriks most recent position was the CEO of ScandiNova, a world leading company in pulsed power and microwave systems that was within the MedTech Industry and Research. He has previously been the Export Director at ETAC AB, which develops, manufactures, and sells medical devices. Board member of Abilia, a Medtech company that is part of the MedCap group. Fredrik has an MScBA in International Economics.

Fredrik's main responsibility will be to support the subsidiaries' management teams in achieving the Group's organic financial goals.

“Strengthening ADDvise with Fredrik Mella enables us to continue to accelerate our growth rate. He will complement our management team with his international experience from the Medtech industry, and I believe Fredrik will be a good leader and coach for our subsidiaries' CEOs,” says CEO Rikard Akhtarzand.

“ADDvise is a successful company in the middle of an exciting growth journey. I look forward to make a difference and contribute with my experiences ", says Fredrik Mella.

Fredrik will assume office on February 17, 2022.

Latest press releases

ADDvise signs Letter of Intent to acquire CliniChain Holding B.V.

Regulatory

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of CliniChain Holding B.V. (”CliniChain”) regarding an acquisition of 100 percent of the shares in CliniChain. CliniChain is a fast-growing international medtech equipment provider for clinical studies. The company offers tailored rental and purchase solutions of medtech equipment that are adapted to…

ADDvise receives order worth USD 640,000

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Hortman Health Care Investment LLC, an investment company in the private healthcare sector, based in the United Arab Emirates. The order is worth approximately USD 640,000 and involves design, supply, and installation of a stem cell laboratory for a clinic in Dubai, United…

Interim report January 1 – June 30, 2022

Regulatory

April-June 2022 Orders received for the period was SEK 260.9 million (122.8), an increase of 112.5 %. Organic growth was 22.3 %. Net revenue for the period was SEK 231.9 million (117.6), an increase of 97.1 %. Organic growth was 3.1 %. Adjusted EBITDA for the period was SEK 31.8 million (15.5) EBITDA for the…

ADDvise receives allocation decision worth approximately EUR 2.4 million

Regulatory

ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from Helsinki University Hospital in Finland regarding digital x-ray equipment with a total value of approximately EUR 2.4 million. Installations are expected to take place during the year 2022 and 2023. In accordance with Finnish procurement law the allocation decision can be appealed…